Looking for a Better Alternative to Chemotherapy for AL Amyloidosis

Caelum Biosciences, a Fortress Biotech company, is a clinical-stage biotech developing treatments for rare and life-threatening diseases. It’s lead therapeutic in development is a novel antibody to treat patients with amyloid light chain amyloidosis, a rare disorder of the bone marrow that causes misfolded proteins to accumulate in tissue and organs throughout the body and cause damage. We spoke to Michael Spector, president and CEO of Caelum, about the company’s business model, its lead therapeutic, and how the competitive landscape for a rare disease therapy may shape development strategies.